Parenteral peramivir treatment for oseltamivir-resistant 2009 pandemic influenza a H1N1 viruses

Journal of Infectious Diseases

Volumn 204, Issue 10, 2011, Pages 1641-1642

  Abed, Yacine ^a   Boivin, Guy ^a   Yoshida, Ryu ^b   Kodama, Makoto ^b   Hernandez, Jaime E ^c  

^a LAVAL UNIVERSITY   (Canada)

^b SHIONOGI AND CO LTD   (Japan)

^c BIOCRYST PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; OSELTAMIVIR; PERAMIVIR; ZANAMIVIR;

2009 H1N1 INFLUENZA; BINDING AFFINITY; CONCENTRATION RESPONSE; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SENSITIVITY; GENE MUTATION; LETTER; MORTALITY; MULTIPLE CYCLE TREATMENT; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK REDUCTION; SINGLE DRUG DOSE; SURVIVAL RATE; VIRUS INHIBITION; WEIGHT REDUCTION;

ANIMALS; ANTIVIRAL AGENTS; DRUG RESISTANCE, MULTIPLE, VIRAL; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; MALE; ORTHOMYXOVIRIDAE INFECTIONS;

EID: 80054724649     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir610     Document Type: Letter

References (10)

1. Memoli JM, Davis AS, Proudfoot K, et al. Multidrug-resistant 2009 pandemic influenza A(H1N1) viruses maintain fitness and transmissibility in ferrets. J Infect Dis 2011; 203:348-57.
2. Memoli JM, Hrabal RJ, Hassantoufighi A, Eichelberger MC, Taubenberger JK. Rapid selection of oseltamivir-and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts. Clin Infect Dis 2010; 50:1252-5.
3. Gubareva LV, Trujillo A, Okomo-Adhiambo M, et al. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro. Antivir Ther 2010; 15:1151-9.
4. Centers for Disease Control and Prevention. Flu activity and surveillance. http://www.cdc. gov/flu/weekly/fluactivitysurv.htm. Accessed 29 March 2011.
5. Gubareva LV, Okomo-Adhiambo M, Deyde V, et al. Update: drug susceptibility of swineorigin influenza A (H1N1) viruses, April 2009. MMWR Morb Mortal Wkly Rep 2009; 58: 433-5.
6. Bantia S, Parker CD, Ananth SL, et al. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir. Antimicrob Agents Chemother 2001; 45:1162-7. (Pubitemid 32230997)
7. Atiee G, Lasseter K, Baughman S, et al. Absence of pharmacokinetic interaction between intravenous peramivir and oral oseltamivir or rimantadine in humans. J Clin Pharmacol. In press.
8. Kohno S, Kida H, Mizuguchi M, et al. Intravenous peramivir for treatment of influenza A and B infection in high-risk patients. Antimicrob Agents Chemother 2011; 55:2803-12.
9. Boivin G, Goyette N. Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors. Antivir Res 2002; 54:143-7. (Pubitemid 34327680)
10. Abed Y, Simon P, Boivin G. Prophylactic activity of intramuscular peramivir in mice infected with a recombinant influenza A/ WSN/33 (H1N1) virus containing the H274Y neuraminidase mutation. Antimicrob Agents Chemother 2010; 54:2819-22.